Pharmacokinetics of treosulfan in a myeloablative combination with cyclophosphamide prior to allogeneic hematopoietic stem cell transplantation.

International journal of clinical pharmacology and therapeutics

Volumn 42, Issue 11, 2004, Pages 654-655

  Hilger, R A ^a   Baumgart, J ^a   Scheulen, M E ^a   Trenschel, R ^a   Strumberg, D ^a   Seeber, S ^a   Beelen, D W ^a  

^a UNIVERSITY OF ESSEN MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; BUSULFAN; CYCLOPHOSPHAMIDE; DRUG DERIVATIVE; MYELOABLATIVE AGENT; TREOSULFAN;

AREA UNDER THE CURVE; ARTICLE; HALF LIFE TIME; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA; METABOLIC CLEARANCE RATE; TISSUE DISTRIBUTION;

ANTINEOPLASTIC AGENTS, ALKYLATING; AREA UNDER CURVE; BUSULFAN; CYCLOPHOSPHAMIDE; HALF-LIFE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA; METABOLIC CLEARANCE RATE; MYELOABLATIVE AGONISTS; TISSUE DISTRIBUTION; TRANSPLANTATION CONDITIONING;

EID: 16644395008     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP42654     Document Type: Article

References (0)